Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HT-003 vs Gliatilin in Healthy Males
NCT02395926Phase 1Completed
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Oct 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of choline alfoscerate in cognitive impairment (3 arms), sponsored by Hyundai Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Curve to the Last Measurable Concentration at 24 hours. Started Oct 2013; status: completed.
02
Drugs
choline alfoscerate
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT02395926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395926.